Abstract:BackgroundImmunologic memory against vaccine-preventable diseases is often lost after an allogeneic hematopoietic cell transplant (allo-HCT), therefore recipients are required to be re-immunized after allo-HCT to regain immunity against these infections. But the response to vaccination after an allo-HCT can be highly variable and is not well understood. We performed a single center retrospective study to examine immunization practices and determine the rate of vaccine protection and seroconversion following vaccination after allo-HCT.MethodsElectronic medical records (EMR) from patients ≤18 years of age who underwent allo-HCT at St. Jude Childrens' Research Hospital between 2005 - 2021 were reviewed. Clinical information and serology results before and after completion of the immunizations series were extracted from the EMR. The vaccines included in this analysis were diphtheria, measles, mumps, rubella (MMR), varicella, and polio. Protection was evaluated only for infections with established immune correlates. Seroconversion was defined as 4-fold increase in titers for vaccines with quantitative antibody assays, or as a change from negative to positive IgG for vaccines with qualitative antibody tests.Results760 patients were included in this cohort. Demographic and clinical data are summarized in Table 1. The mean age at allo-HCT was 10.4 years, most were male (56.8%) and white (74.6%). Acute leukemia accounted for 66.4% of allo-HCT recipients. Conditioning was myeloablative for 53.45%, and reduced intensity for 37.9%. Most received transplants from mismatched-related donors, (44.9%), followed by matched unrelated donors (35.4%) and matched related donors (19.5%). The number of patients who received the full vaccination series at our institution differed by vaccine and ranged from 41-150, and the respective subsets with available pre-vaccination and post-vaccination titers ranged from 24-93. The median time from transplant to initiation of immunizations was 12 months (range: 6-58) for non-live vaccines, 25 months (range: 23, 63) for MMR vaccine, and 28 months (range: 16, 117)) for varicella vaccine. Protection post immunization varied, with less patients demonstrating protections for mumps (79%) and measles (82%) (Figure 1). Seroconversion also varied among the different vaccine components and types of vaccines.ConclusionCurrent strategies to re-immunize patients after allo-HCT do not provide protection to all patients. Understanding the factors associated with suboptimal immune responses is critical for advancing our knowledge in this area. Whether time-based approaches combined with immune reconstitution data are required to further optimize protection remains unclear. Additionally, different vaccine schedules (i.e., higher doses) may be required in these patients.Table 1: Demographic and transplant characteristics Overall (N=760) Age at HSCT (years) Mean (SD)10.4 (6.16)Median [Min, Max]10.6 [0.0684, 27.2] Race White567 (74.6%)Black131 (17.2%)Asian23 (3.0%)Mixed18 (2.4%)Other16 (2.1%)Native American5 (0.7%) Gender Female328 (43.2%)Male432 (56.8%) Diagnosis ALL230 (30.3%)AML274 (36.1%)Myelodysplastic Syndrome33 (4.3%)Other leukemias/lymphomas66 (8.7%)Aplastic Anemia50 (6.6%)Sickle Cell Anemia24 (3.2%)Solid tumors18 (2.4%)Other conditions65 (8.6%) Conditioning Regimen Myeloablative406 (53.4%)Reduced Intensity288 (37.9%)No preparative regimen1 (0.1%)Missing65 (8.6%) Graft product type Peripheral Blood Derived Stem Cells391 (51.4%)Bone Marrow363 (47.8%)Missing6 (0.8%) Donor type Mismatched Related341 (44.9%)Matched Related148 (19.5%)Matched Unrelated269 (35.4%)Missing2 (0.3%) Figure 1. Protection and seroconversion rate by vaccine target.

Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

Comparable CD8+ T‐cell responses to SARS‐CoV‐2 vaccination in single‐cell transcriptomics of recently allogeneic transplanted patients and healthy individuals

Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments

Antibody responses to re-immunization in recipients of allogeneic hematopoietic cell transplantation

SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study

Spike-Specific Memory B Cell Response in Hematopoietic Cell Transplantation Recipients following Multiple mRNA-1273 Vaccinations: A Longitudinal Observational Study

Early Immune Surveillance to Predict Cytomegalovirus Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.

Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients

SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients

#5548 THE PROGNOSTIC VALUE OF LYMPHOCYTE SUBSETS IN ANTIBODY RESPONSE AFTER SARS-COV2 VACCINATION IN DIALYSIS PATIENTS AND KIDNEY TRANSPLANT RECIPIENTS

Impaired SARS-CoV-2-specific responses via activated T follicular helper cells in immunocompromised kidney transplant recipients

Immunogenicity and Tolerance of BNT162b2 mRNA Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Patients

Antigen-specific T helper cells and cytokine profiles predict intensity and longevity of cellular and humoral responses to SARS-CoV-2 booster vaccination

Re‐vaccination against SARS‐CoV‐2 in allogeneic HSCT patients: Repeated primary vaccine doses increase seroconversion rates

Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation

Development of T-cell immunity in a liver and hematopoietic stem cell transplant recipient following coronavirus disease 2019 infection

Humoral and T-cell response 12 months after the first BNT162b2 vaccination in solid organ transplant recipients and controls: Kinetics, associated factors, and role of SARS-CoV-2 infection

Cellular immune response of SARS-CoV-2 vaccination in kidney transplant recipients: a systematic review and meta-analysis

Immunophenotypic predictors of influenza vaccine immunogenicity in pediatric hematopoietic cell transplant recipients